Leerink Partnrs Issues Optimistic Forecast for ELDN Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities research analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.26) for the quarter, up from their prior forecast of ($0.29). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.19) EPS and FY2029 earnings at ($0.50) EPS.

Separately, Guggenheim began coverage on Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Stock Up 0.7%

Shares of ELDN stock opened at $3.06 on Monday. Eledon Pharmaceuticals has a 12-month low of $2.30 and a 12-month high of $5.54. The firm has a fifty day moving average of $3.15 and a 200-day moving average of $3.92. The firm has a market capitalization of $183.24 million, a price-to-earnings ratio of -1.52 and a beta of 0.08.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.20.

Institutional Trading of Eledon Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC boosted its holdings in shares of Eledon Pharmaceuticals by 83.7% in the first quarter. Jane Street Group LLC now owns 224,600 shares of the company’s stock valued at $761,000 after buying an additional 102,325 shares during the period. Zimmer Partners LP boosted its stake in Eledon Pharmaceuticals by 0.7% in the 1st quarter. Zimmer Partners LP now owns 754,970 shares of the company’s stock worth $2,559,000 after purchasing an additional 4,970 shares during the period. Goldman Sachs Group Inc. boosted its stake in Eledon Pharmaceuticals by 78.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 258,106 shares of the company’s stock worth $875,000 after purchasing an additional 113,261 shares during the period. Siren L.L.C. bought a new position in Eledon Pharmaceuticals during the 1st quarter worth about $2,340,000. Finally, 22NW LP acquired a new stake in shares of Eledon Pharmaceuticals in the 1st quarter valued at about $2,157,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).